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Abstract
Pancreatic cancer patients have an abysmal prognosis
because of late diagnosis and lack of therapeutic op-
tions. Pancreatic intraepithelial neoplasias (PanINs),
the precursor lesions, are a potential target for che-
moprevention. Targeting eicosanoid pathways is an
obvious choice because 5-lipoxygenase (5-LOX) has
been suggested as a tumor promoter in pancreatic
carcinogenesis. Here we provide evidence that 15-
lipoxygenase-1 (15-LOX-1) expression and activity may
exert antitumorigenic effects in pancreatic cancer. Re-
verse transcription–polymerase chain reaction (RT-
PCR) and Western blot analysis showed absence or
very weak expression of 15-LOX-1 in all pancreatic
cancer cell lines tested. 15-LOX-1 was strongly stained
in normal ductal cells, tubular complexes, and centro-
acinar cells, but no staining was seen in islets, cancer
cells, PanIN lesions, or in tumor cells in lymph node
metastases, indicating that 15-LOX-1 expression is
lost during tumor development in human pancreas.
Overexpression of 15-LOX-1 in pancreatic tumor cells
or treatment with its arachidonic acid–derived metabo-
lite resulted in decreased cell growth. These findings
provide evidence that loss of 15-LOX-1 may play an im-
portant role in pancreatic carcinogenesis, possibly as
a tumor suppressor gene. Thus, induction of 15-LOX-1
expression may be an attractive option for the pre-
vention and treatment of pancreatic cancer.
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Introduction
In the last decade, death rate from all cancers combined
has decreased by 1.5% per year among men and by 0.8%
per year among women, whereas the mortality rate has
decreased from lung, colorectal, prostate, and breast can-
cer, but not pancreatic cancer [1]. In the US, 33,730 new
cases as well as 32,300 deaths from pancreatic cancer are
estimated in 2006 [1]. Pancreatic cancer is the fourth leading
cause of cancer-related death in the US and ranks third in men
between 40 and 59 years of age [1]. This devastating cancer is
one of the cancer sites for which survival has not improved
substantially over the past 25 years [2]. The overall 5-year
relative survival rate has only increased from 3% to 5% within
the last three decades [1]. Incidence and mortality rates are
equal between men and women and have not declined since
1930 [1]. Indeed, incidence has increased in Japanese and
African Americans over recent decades [3–5]. Pancreatic
cancer has an abysmal prognosis because of late diagnosis
and lack of therapeutic options. Only 9% to 20% of patients
proceed to surgical resection and even with surgery; these
patients often have poor long-term survival [6]. Many patients
have recurrent disease by 12 months after surgery [6]. The 2-
and 5-year survival times are at about 40% and 20%, respec-
tively, and the median survival time is 19 months when patients
receive adjuvant chemotherapy [7,8]. Thus, new targets need
to be identified for early diagnosis, prevention, and treatment
of this disastrous disease [9]. Pancreatic intraepithelial neo-
plasias (PanINs) are the histologically defined precursor
lesions of pancreatic cancer in the small ducts and ductules.
PanINs are an ideal target for chemoprevention or early treat-
ment [10–12].
The results from epidemiological and animal studies suggest
that a high fat consumption is associated with an increased
incidence and growth of tumors at several specific organ sites
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including pancreas, colon, breast, and prostate [13–16]. In
these tissues, it has been demonstrated that linoleic acid
promotes carcinogenesis [17].
Recent reviews have highlighted the importance of li-
poxygenase pathways in fat metabolism and in the regulation
of pancreatic cancer cell proliferation and survival [18,19].
Lipoxygenases (LOXs) are lipid-peroxidizing enzymes that
are categorized according to their position in the oxygena-
tion of arachidonic acid, e.g. 15-lipoxygenase (15-LOX) oxy-
genates arachidonic acid at C-15 [20]. 15-Lipoxygenase-1
(15-LOX-1) metabolizes not only linoleic acid, the pre-
dominant polyunsaturated fatty acid in the human diet,
to 13(S )-hydroxyoctadecadienoic acid (13(S )-HODE) but
also arachidonic acid to 15(S )-hydroxyeicosatetraenoic acid
(15(S )-HETE) and it is expressed in reticulocytes, eosino-
phils, macrophages, and the airway epithelium [20,21]. Nu-
merous clinical studies on LOX expression in human tumors
as well as in animal models indicate different roles of the dis-
tinct LOX isoforms in carcinogenesis [22,23]. In fact, different
LOX isoforms exhibit either protumorigenic or antitumorigenic
activities and modulate the tumor response in a tissue-specific
manner. Data suggest that the 5-LOX and platelet-type 12-LOX
exhibit procarcinogenic activities, whereas 15-LOX-1 and 15-
LOX-2 may suppress carcinogenesis.
In pancreatic carcinogenesis, 5-LOX has been suggested
to be a new tumor promoter, because it is upregulated in pan-
creatic cancer cells, in all gradesof humanPanINs, and inearly
lesions of pancreatic cancer in two different animal models
(EL-Kras mice and N-nitroso-bis(2-oxopropyl)amine-treated
hamsters) [24–26].
In contrast, 15-LOX-1 is downregulated in human esoph-
ageal, gastric, colorectal, and breast carcinomas and non-
steroidal antiinflammatory drugs can induce apoptosis in
these cancer cells independently of cyclooxygenase-2
(COX-2) inhibition [17,27–31]. Furthermore, downregulation
of 15-LOX-1 seems to be an early event in the adenoma
to carcinoma sequence of the colon [30]. In the past, con-
flicting data on 15-LOX-1 expression in colorectal carcino-
mas were published, since one group described elevated
levels of 15-LOX-1 in human colon tumors [20]. However, the
current working hypothesis is that expression of 15-LOX-1
exerts an antitumorigenic effect in the colon but is protu-
morigenic in the prostate [32–34]. In addition, 15-LOX-1 has
been suggested as a tumor suppressor gene, because low
micromolar concentrations of either 5-aza-2-deoxycytidine
(5-Azadc) [a potent methyltransferase inhibitor (MTI)] or
suberoylanilide hydroxamic acid (a histone deacetylase in-
hibitor) induce the expression of 15-LOX-1 in human colorec-
tal cancer cells, causing growth arrest, differentiation, and/or
apoptosis [35].
To date, nothing is known about the role of 15-LOX-1 in
pancreatic cancer. Therefore, in the present study, we in-
vestigated the expression of 15-LOX-1 in normal and path-
ologic pancreatic tissues and the effect of 15-LOX-1
expression on pancreatic cancer cell proliferation. We were
curious whether or not 15-LOX-1 could serve as a new tumor
suppressor and whether or not it can be used as a potent
therapeutic target in the fight against pancreatic cancer.
Materials
RPMI 1640, Dulbecco’s modified Eagle’s medium (DMEM),
DMEM/Ham’s F12, penicillin–streptomycin solution, and
trypsin–EDTA solution were purchased from Gibco (Invitro-
gen, Karlsruhe, Germany). FBS was from PAA (PAA Labo-
ratories, Co¨lbe, Germany). The 15-LOX-1 antibody was
a generous gift from Dr. Mary Mulkins (Roche Bioscience,
Palo Alto, CA). 15(S)-HETE was purchased from Cayman
(Cayman Chemicals, Ann Arbor, MI).
Cell Lines and Cell Culture
The cell lines used, i.e., PANC-1, Capan I, Capan II,
MiaPaCa2, AsPC-1, and S2-O13, were established from
patients with pancreatic adenocarcinoma. All of the human
pancreatic cancer cell lines, except S2-O13, were purchased
from the American Type Culture Collection (ATCC, Rockville,
MA). S2-O13 cells were provided by Dr. M. A. Hollingsworth
(Eppley Cancer Institute, Omaha, NE). A normal pancreatic
epithelial cell line (AMA) from bovine origin was kindly
provided by Dr. R. Jesenofski and Prof. M. Lo¨hr (Deutschen
Krebsforschungszentrum, Heidelberg, Germany).
S2-O13 and MiaPaCa2 were cultured in DMEM. Capan I,
Capan II, AsPC-1, and PANC-1 were grown in RPMI 1640.
AMA cells were cultivated in DMEM/Ham’s F12.
Media were supplemented with 10% FBS and 1% peni-
cillin–streptomycin and cells were grown as monolayers in a
humidified atmosphere of 5% CO2 at 37jC. Adherent cells
were detached by trypsinization with 1 ml trypsin–EDTA so-
lution (Gibco, Invitrogen).
Stable Transfection
The plasmids of pcDNA3.1 and pcDNA3.1–15-LOX-1
containing the coding region of human 15-LOX-1 were trans-
fected into MiaPaCa2 and S2-O13 cells according to the
manufacturer’s protocol using a reagent (Lipofectamine
2000; Invitrogen). After 24 hours, fresh medium was added
to the cells containing the selection reagent G418 (100 mg/ml)
(Sigma-Aldrich, Munich, Germany). Selection was continued
for 1 week, with the medium being refreshed every alternate
day. After 1 week, cells were maintained at 20 mg/ml G418.
Clones were isolated and 15-LOX-1 overexpression was
confirmed by Western blot and activity assay analyses.
Reverse Transcription–Polymerase Chain Reaction
(RT-PCR) for 15-LOX-1
Total RNA from Su8686, PANC-1, MiaPaCa2, BxPc3,
AsPC-1, Capan I, Capan II, Colo357, T3M4, S2-O13, and
AMA cells as well as from human monocytes was isolated
according to the manufacturer’s protocol using a purification
kit (GenElute Mammalian Total RNA Kit; Sigma-Aldrich,
Munich, Germany). To ensure purity, the isolated RNA was
treated with DNAse I (Sigma-Aldrich, Munich, Germany).
The final reaction volume was 15 ml, containing 5 mg of
RNA, 0.5 ml of DNAse I, 1.5 ml of PCR buffer, and water.
Before adding 2.5 ml of 10 mM EDTA, the mix was incu-
bated at 37jC for 15 minutes. Subsequently, the mix was
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incubated at 65jC for 20 minutes and then cooled down for
5 minutes at 4jC.
Cellular RNA was reverse-transcribed into cDNA accord-
ing to the manufacturer’s protocol (GeneAmp RNA PCR
Core Kit; Applied Biosystems, Foster City, CA). The total
reaction volume was 20 ml containing the following: 1 mg of
total RNA, 25 mM MgCl2, 2 ml of 10 PCR buffer II, 2 ml of
deoxyribonucleotide triphosphates (10 mM), 1 ml of RNase
inhibitor (20 U/ml), 1 ml of murine leukemia virus reverse tran-
scriptase (50 U/ml), 1 ml oligo dT primer and RNase/DNase–
free water. The thermocycler protocol for the RT phase is one
cycle at 20jC for 10 minutes, 42jC for 15 minutes, and one
cycle at 99jC for 5 minutes.
After the RT reaction, 1 ml of the cDNA obtained from RT-
PCR was used for 15-LOX-1-specific PCR. Primers were
designed based on the sequence of human or bovine 15-
LOX-1, respectively (Table 1).
The PCR profile was one cycle at 94jC for 5 minutes,
94jC for 1.5 minutes, 56jC for 1.5 minutes, and 36 cycles at
72jC for 2.5 minutes. The same PCR profile was used to
verify bovine 15-LOX-1. As a control, b-actin PCR was per-
formed using human and bovine primer sequences (Table 1).
The final PCR product was separated on 1% agarose gel
containing ethidium bromide.
Western Blot Analysis for 15-LOX-1
Western blot analysis was carried out to determine the
specificity of the 15-LOX-1 antibody, the expression of 15-
LOX-1 in tumor cell lines, and to confirm 15-LOX-1 overex-
pression in transfected MiaPaCa2 and S2-O13 cells.
Cells seeded onto 100-mm dishes were lysed (50 mM
Tris, pH 7.4, 1 mM EDTA, 1 mM EGTA, and 1 mM aprotinin)
and sonicated, using ultrasound three times for 10 seconds.
The protein content of lysates was measured using bicin-
choninic acid assay (Pierce Biotechnology, Rockford, IL).
Proteins in 10 mg of each pancreatic cancer cell lysate
were separated by sodium dodecyl sulfate–polyacrylamide
gel electrophoresis (SDS–PAGE 4–12%) (NU-Page;
Invitrogen). Proteins were transferred to nitrocellulose mem-
branes (BioRad, Hercules, CA) by electroblotting using a
transfer blotting apparatus (NU-Page; Invitrogen).
Nitrocellulose membranes were subsequently blocked in
Tris-buffered saline (TBS) containing 5% nonfat milk and
0.1% Tween-20, then treated with 15-LOX-1 antiserum at
1:10,000 dilution in 5% nonfat milk, TBS containing 0.1%
Tween-20 overnight at 4jC. After washing, the membrane was
incubated with horseradish peroxidase (HRP)–conjugated
goat anti– rabbit antibody at 1:2000 dilution for 1 hour.
15-LOX-1 protein was detected by chemiluminescence treat-
ment (Amersham, Piscataway, NJ) and capture of light emis-
sion on an X-ray film (Fujifilms, Du¨sseldorf, Germany).
LOX Activity Assays
LOX activity was quantified by measuring HETE forma-
tion in cell-free protein extracts. The amount 250 mg of
cytosolic protein homogenates were incubated with 100 mM
arachidonic acid for 15 minutes at 37jC. The incubations
were terminated by the addition of 40 ml of 1 M sodium for-
mate buffer (pH 3.1) and products were extracted by with a
modification of the Bligh and Dyer procedure as described
[36]. Products were analyzed by reverse-phase HPLC on a
5-mm YMC-Pack ODS-AM column (25  0.46 cm2, YMC
Europe, Schermbeck, Germany) with a 1-cm guard col-
umn using the solvent system of methanol/water/acetic acid
(82:18:0.01 by volume) and a flow rate of 0.5 ml/min. Elu-
tion was monitored at 235 nm with a diode array detector
(Bio-Tek Kontron 540; Kontron Instruments, Neufahrn, Ger-
many). The products were identified by comparing retention
times and peak areas with those of authentic external 15(S)-
HETE standard (Reatec, Weiterstadt, Germany). The reten-
tion time for 15(S)-HETE was 28.0 minutes.
Treatment with 15(S)-HETE
To examine the responsiveness of pancreatic cancer
cells to 15(S)-HETE, MiaPaCa2 and S2-O13 cells were
treated with 0.5 and 1 mM 15(S)-HETE for 24 to 120 hours
and cell proliferation was measured by cell counting using
a Neubauer chamber and Guava PC (Guava Technologies,
Inc., Hayward, CA).
At the beginning, 50,000 cells were seeded into 60-mm
dishes. After 24 hours, the medium was replaced by medium
containing 15(S)-HETE (2 ml/dish). Medium was changed
again 72 hours after induction. As a negative control, cells
were treated with the solvent (ethanol).
Cell Proliferation Analysis
The proliferation of 15-LOX-1–expressing MiaPaCa2
and S2-013 cells was determined by cell counting using a
Neubauer chamber and Guava PC (Guava Technologies).
MiaPaCa2–15-LOX-1 and S2-O13–15-LOX-1 stably
transfected and MiaPaCa2–Mock– and S2-O13–Mock–
transfected cells were seeded at 2.5  104/ml into 60-mm
culture dishes. Each dish contained 5  104 cells at the
starting point. Triplicates were counted every 24 hours up to
120 hours. This experiment was repeated three times.
Additionally, cell proliferation was measured using the
WST-1 assay from Roche (Roche Diagnostics, Mannheim,
Germany) according to the manufacturer’s protocol. A total
Table 1. 15-LOX-1 Primer Sequences.
5V Primer 3V Primer
15-LOX-1 (human) 5V–CATCTATCGGTATGTGGA–3V 5–GAAGTTGGGCAGTGTC–3V
15-LOX-1 (bovine) 5V–CGGTGGCTCAGTGGTAAAG–3V 5V–ACCATGAGGTGCTTCCGTCT–3V
Actin (human) 5V–CTTCCTGGGCATGGAGTCCT–3V 5V–CCGCCGATCCACACAGAGTA–3V
Actin (bovine) 5V–CGGCATTCACGAAACTACCTT–3V 5V–TAGAAGCATTTGCGGTGGA–3V
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of 1000 cells of each cell line, i.e., MiaPaCa2–15-LOX-1,
MiaPaCa2–Mock, S2-O13–15-LOX-1 and S2-O13–Mock,
were plated into six wells of a 96-well plate using a 100-
ml per well cell culture volume. A total of 10 ml of the ready-to-
use WST-1 reagent was added to the cells and incubated
for 1 hour at 37jC under 5% CO2 atmosphere. As a nega-
tive control, cell culture medium alone was used. The absor-
bance of the samples was measured against the background
using a microplate reader at a wavelength of 450 nm.
Measurement of Apoptosis
MiaPaCa2–15-LOX-1 and S2-O13–15-LOX-1 stably
transfected cells were seeded at 2.5  104/ml into 60-mm
culture dishes. Each dish contained 5  104 cells at the
starting point. Annexin V binding (Nexin Assay; Guava
Technologies) was performed according to the manufactur-
er’s protocol. About 120 hours after seeding, cells were
trypsinized and centrifuged at 350g for 10 minutes at 4jC.
The supernatant was removed and the pellet was washed
with 1 ml of cold Nexin buffer. The supernatant was removed
and the pellet was resuspended in 1 ml of cold Nexin buffer.
The cell number was adjusted to 200,000 cells/ml. The
amounts 5 ml of Annexin V–PE and 5 ml of 7-AAd were added
to 40 ml of cell suspension in 1 Nexin buffer, shortly
vortexed, and then the reaction was incubated shielded from
light, on ice for 20 minutes. A total of 450 ml of cold Nexin
buffer was added to each reaction tube, vortexed, and then
acquired on the Guava PC (Guava Technologies).
Immunohistochemistry for 15-LOX-1
Eleven surgical pancreatic specimens were obtained from
patients with chronic pancreatitis and twelve were from
pancreatic adenocarcinoma. Twelve pancreas specimens
from multiorgan donors were included as controls. In addi-
tion, nine lymph node metastases and five liver metastases
from patients with pancreatic cancer were included. The
Human Subjects Committee at the University of Heidelberg,
Germany, approved this study.
All specimens were fixed in 10% buffered formalin, paraffin-
embedded, and processed for histology using conventional
methods. Sections (4 mm thick) were prepared from the par-
affin blocks. After deparaffinization, the slides were sub-
merged in methanol containing 0.3% hydrogen peroxide for
30 minutes at room temperature to inhibit endogenous peroxi-
dase activity. Thereafter, slides were washed in Tris-buffered
saline (TBS; 0.1 M, pH 7.4). The slides were incubated with
normal goat serum for 30 minutes at room temperature and
then with the primary antibody directed against 15-LOX-1 (rab-
bit polyclonal, diluted 1:2500 in TBS containing 1% BSA) for
18 hours at 4jC. The slides were then washed again in TBS
and incubated with biotinylated secondary anti–rabbit anti-
body (Multilink; Bio Genex, San Ramon, CA) for 10 minutes at
37jC. Detection of the antibody complex was performed by the
streptavidin–peroxidase reaction kit using DAB as chromo-
gen. To ensure the specificity of the primary antibody, control
tissue sections were incubated in the absence of primary
antibody. Counterstaining was performed with Hematoxylin
Gil No. 2 (Sigma-Aldrich, St. Louis, MO). The stained tissue
samples were verified by two pathologists.
Statistical Analysis
Data on 15-LOX-1 expression by immunohistochemistry
in humans were analyzed by analysis of variance (ANOVA)
with the Student-Newman-Keuls post hoc test for multi-
ple comparisons. Paired t-test and Friedman’s repeated-
measures ANOVA on ranks (with Tukey’s post hoc test for
pairwise multiple comparison procedures) were used to
analyze cell proliferation (WST-1 and cell counting).
Results
15-LOX-1 Expression in Pancreatic Tissues
15-LOX-1 expression in normal and neoplastic pancreas
was analyzed by immunohistochemistry. The staining pat-
tern indicated strong expression of 15-LOX-1 in normal duc-
tal cells in normal as well as in diseased pancreas. However,
larger ducts, e.g., the main pancreatic duct, did not stain
for 15-LOX-1 in most biopsies. Furthermore, tubular com-
plexes in normal, diseased, or neoplastic tissues showed
marked expression of 15-LOX-1. However, tubular com-
plexes were stained in only 6/12 normal pancreatic tissues
but in all tissues obtained from patients with chronic pan-
creatitis (11/11) and pancreatic adenocarcinoma (12/12).
In addition, centroacinar cells were positive for 15-LOX-1
whereas other acinar cells did not stain. Whenever 15-LOX-1
was expressed, the staining was specific and granular in the
cytoplasm. Interestingly, PanIN-1 lesions were positively
stained for 15-LOX-1, but more advanced PanIN lesions
were negative. No expression of 15-LOX-1 was demonstrated
in islet or cancer cells. Clearly, inside the peripancreatic lymph
node metastases (9/9), as well as liver metastases (5/5),
macrophages, but not metastatic cancer cells, stained positive
for 15-LOX-1 (Figure 1). Detailed information on histology and
staining intensity is shown in Table 2.
Generation of Stable 15-LOX-1–Expressing Pancreatic
Cancer Cell Lines
Expression of 15-LOX-1 in various human pancreatic
cancer cell lines was analyzed by RT-PCR and Western blot
analysis. 15-LOX-1 mRNA and protein expression was be-
low the level of detection in all cancer lines tested including
Su8686, PANC-1, MiaPaCa2, BxPc3, AsPC-1, Capan I,
Capan II, Colo357, T3M4, and S2-O13 (Figure 2). Lysates
from human monocytes and HEK293 cells transiently ex-
pressing 15-LOX-1 were used as positive controls. In con-
trast, strong 15-LOX-1 mRNA expression was detected in
normal ductal cells of bovine (AMA) origin (data not shown).
This immortalized bovine ductal cell line was used because
a normal human ductal cell line is not available. The poly-
clonal antibody was specific for 15-LOX-1 and did not de-
tect any of the other human lipoxygenases (data not shown).
The data suggest that 15-LOX-1 expression is lost during
tumor development.
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The eukaryotic expression vector pcDNA3 carrying the
cDNA under the control of the cytomegalovirus promoter
was used to stably express 15-LOX-1 in pancreatic can-
cer cells. Two cell clones, MiaPaCa2–15-LOX-1–cl13 and
S2-O13–15-LOX-1–cl8, which showed strong expression of
15-LOX-1 by RT-PCR and Western blot analysis were se-
lected for further experiments (Figure 3). The enzymatic
activity of 15-LOX-1 in both cell lines was confirmed by
the formation of 15(S)-HETE in protein lysates on incubation
with arachidonic acid; whereas in mock-transfected clones
expressing the vector construct, no 15(S)-HETE production
was observed (Figure 4).
Effects of 15-LOX-1 Overexpression and 15-LOX-1
Metabolites on Tumor Cell Proliferation
When compared with mock-transfected cells, 15-LOX-1
overexpression significantly inhibited the proliferation of Mia-
PaCa2 and S2-O13 cells, as measured by both cell count-
ing (P < .001) and WST-1 assay (P = .0003 and P = .001)
(Figure 5, A and B). Highly significant differences (P < .0001)
in the cell numbers were observed at 96 and 120 hours
after seeding.
Treatment of the parental MiaPaCa2 and S2-O13 cells
with the arachidonic acid–derived 15-LOX-1 product 15(S)-
HETE caused growth inhibition by 17% at 0.5 mM (data not
shown) and by 21% at 1 mM concentration (P < .001), with
markedly reduced cell numbers at 96 and 120 hours (P <
.0001) (Figure 6A). In contrast, addition of the linoleic acid
product 13(S)-HODE did not affect cell proliferation at 1 mM
but only at 50 mM and more (not shown). No additional
growth-inhibitory effect was observed by exogenous 15(S)-
HETE in 15-LOX-1–overexpressing cells MiaPaCa2–15-
LOX-1 and S2-O13–15-LOX-1.
To understand the growth-inhibitory effect, we investigated
apoptosis by performing annexin V binding and examined
cell cycle distribution by FACS analysis. Overexpression of
15-LOX-1 in pancreatic cancer cells caused apoptosis (Fig-
ure 6B), whereas no change in cell cycle was observed (data
not shown).
Discussion
At present, the best chance to improve on statistics for pan-
creatic cancer would be prevention or early detection before
this cancer becomes invasive, because no effective treatment
is available. Even small resectable tumors recur in most cases
within 2 years after primary surgery or have metastasized,
which becomes evident months or years later. Chemotherapy
only prolongs life by a matter of weeks, maintaining the un-
changed abysmal prognosis of pancreatic cancer.
Figure 1. Expression of 15-LOX-1 in human pancreatic tissues. Immunohistochemistry for 15-LOX-1 is shown in panels A to M. (A–D) Different normal human
pancreas with stained ductal cells (A and B) and stained centroacinar cells (C and D) marked by black arrows; magnification,  400. (E) Stained tubular complexes
in chronic pancreatitis (black arrow); magnification,  400. (F and G) Human pancreatic adenocarcinoma with intense positive staining in tubular complexes (black
arrows) but unstained islet (white arrow) (F; magnification,  200) and cancer cells (white arrow) (G; magnification,  400). (H–L) Human pancreatic
adenocarcinoma with intense positive staining in normal ductal cells (black arrow) and tubular complexes (black arrow) but unstained PanIN-2 (white arrow) (H and
I) and PanIN-3 (white arrow) (K) lesions (H, I, and K; magnifications,  200,  400, and  200, respectively) and cancer cells (white arrow) (L; magnification,
 400). (M) Positively stained lymphocytes (black arrow; MU = macrophage) and unstained cancer cells (white arrow; PC = pancreatic cancer cells) in a
lymph node metastasis from pancreatic cancer; magnification,  400. Immunohistochemistry for 15-LOX-1 used a rabbit polyclonal antibody, diluted 1:2500,
and incubated overnight with DAB at 4jC. Panels were counterstained with hematoxylin.
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Table 2. Immunohistochemistry for 15-LOX-1 in Human Pancreatic Tissues.
Sample Normal Ducts Tubular Complexes PanIN Cancer Cells Islet Cells Acini Centroacinar Cells
Normal (CD)
1 + Absent Absent Absent Negative Negative +
2 ++ +++ Absent Absent Negative Negative +++
3 ++ Absent Absent Absent Negative Negative ++
4 ++ Absent Absent Absent Negative Negative +++
5 + ++ Absent Absent Negative Negative ++
6 ++ Absent Absent Absent Negative Negative +++
7 ++ Absent Absent Absent Negative Negative +
8 +++ ++ Absent Absent Negative Negative ++
9 ++ ++ Absent Absent Negative Negative ++
10 (+) Absent Absent Absent Negative Negative ++
11 ++ ++ Absent Absent Negative Negative +++
12 ++ ++ Absent Absent Negative Negative ++
CP
1 + + Negative Absent Negative Negative +
2 Negative +++ Absent Absent Negative Negative +
3 ++ ++ 1a: ++; 2: negative Absent Negative Absent Absent
4 Negative + Negative Absent Negative Negative Negative
5 +++ +++ 1a: +++ Absent Negative Negative +++
6 ++ ++ Absent Absent Negative Negative ++
7 +++ +++ 1a: ++; 2: negative Absent Negative + +++
8 Negative ++ Absent Absent Negative Negative Negative
9 +++ +++ Absent Absent Negative Negative +
10 Negative +++ Absent Absent Negative Negative +
11 +++ +++ 1a/b: +++ Absent Negative Negative +++
PC
1 +++ +++ Negative Negative Negative Negative Absent
2 +++ +++ Negative Negative Negative Negative Absent
3 +++ +++ Negative Negative Negative Negative Absent
4 Absent +++ Negative Negative Negative Negative Absent
5 +++ +++ Negative Negative Negative Negative Absent
6 +++ +++ 1b: + Negative Negative Negative Absent
7 +++ +++ Negative Negative Negative Negative ++
8 ++ ++ Negative Negative Negative Absent Absent
9 ++ +++ Negative Negative Negative Negative ++
10 +++ +++ Negative Negative Negative Negative +++
11 ++ ++ Negative Negative Negative Negative Absent
12 +++ +++ Negative Negative Negative Negative Absent
ANOVA with Student-Newman-Keuls P = .011 P < .001 P = .012 No difference No difference P = .003
Normal vs chronic pancreatitis P = .445 P = .014 P = .017* P = .068
Normal vs pancreatic cancer P = .022 P < .001 P = .786 P = .002
Chronic pancreatitis vs pancreatic cancer P = .011 P = .064 P = .013y P = .076
Because of the multiple groups, statistical analysis in the human samples was carried out by ANOVA with the Student-Newman-Keuls post hoc test for multiple
comparisons.
CD, cadaver donor; CP, chronic pancreatitis; PC, pancreatic cancer; PanIN, pancreatic intraepithelial neoplasia, grades 1a, 1b, 2 and 3.
Absent: described structures are not present in this tissue section.
Negative: unstained but present structures.
+: weak positive staining.
++: positive staining.
+++: strong positive staining.
(+): very weak positive staining.
*No PanIN in CD.
yPanIN-2 and -3 are negative.
Figure 2. Lack of 15-LOX-1 mRNA expression in pancreatic cancer cell lines compared to human monocytes (positive control). Total RNA was isolated, reverse-
transcribed, and then amplified by PCR. The PCR product was separated on 1% agarose gel and visualized by ethidium bromide staining.
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Figure 3.Western blot analysis shows the expression of 15-LOX-1 protein in MiaPaCa2 and S2-O13 cells transfected with pcDNA3.1 (Mock) and pcDNA3.1–15-
LOX-1. Protein lysates from 15-LOX-1– transfected HEK293 cells served as positive controls. Actin expression demonstrates equal loading.
Figure 4. 15-LOX-1 activity in 15-LOX-1–expressing pancreatic cancer cells: reverse-phase HPLC analysis of products formed in cell extracts from stably
transfected MiaPaCa2 and S2-O13 cells. Homogenates from cells were incubated in Tris EDTA buffer with 100 M arachidonic acid for 15 minutes at 37jC.
Products were extracted with methanol/dichloromethane (1:1 by vol.), dried under vacuum, redissolved in methanol/water/acetic acid (82:18:0.01, by vol.), injected
on a 4-m YMC-Pack ODS-H80 column, and eluted at 0.5 ml/min. The eluate was monitored at 235 nm. Authentic 15(S)-HETE was used as standard. The
retention time of 15(S)-HETE was 28.0 minutes.
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The connection between inflammation and cancer goes
back to Virchow in 1863 when he noted a lymphoreticular
infiltrate in neoplastic tissues [37]. He suggested the origin of
cancer in the context of chronic inflammation. Inflammatory
cells and cytokines are more likely to contribute to tumor
growth and progression than to mount the host antitumor
response [37]. In addition, pancreatic cancer is character-
ized by a strong desmoplastic reaction and, in 1986, Dvorak
showed that wound healing and tumor stroma formation
share many important properties. He suggested tumors as
wounds that do not heal [37]. The eicosanoid pathways ap-
pear to play an important role in tumor development, growth,
and progression. For example, cyclooxygenases are the
rate-limiting enzymes in prostaglandin synthesis and it is
well accepted that the inducible isoform, COX-2, plays an
important role in carcinogenesis [19,38]. Furthermore, intake
of nonsteroidal antiinflammatory drugs reduces the risk of
various cancers including colon cancer [39,40]. COX-2 and
5-LOX are expressed in pancreatic adenocarcinomas and
PanINs from malignant and nonmalignant pancreatic tissues
and, recently, 5-LOX has been suggested as a new tumor
promoter in pancreatic carcinogenesis [25,26]. Six human
lipoxygenases have been characterized to date. Whereas
5-LOX and 12-LOX obviously have rather protumorigenic
effects on different tumor cells, the role of 15-LOX-1 is con-
troversial [19]. Expression of 15-LOX-1 is associated with
antitumorigenic effects in the colon but protumorigenic ef-
fects in the prostate, indicating tissue selectivity of LOX
function [32,33]. In the present study, we have, for the first
time, demonstrated expression of 15-LOX-1 in normal ductal
cells, tubular complexes, PanIN-1 lesions and centroacinar
cells, but loss of expression in PanIN-2 or PanIN-3 lesions
and in cancer cells of different human pancreatic tissues.
In addition, inflammatory cells in the stroma of pancreatic
cancers were positively stained, as expected. Curious as to
why normal epithelial cells in the pancreas but not malignant
cells express this enzyme, we investigated the functional role
of 15-LOX-1. In fact, 15(S)-HETE, the arachidonic acid–
derived product of 15-LOX-1, exhibited growth-inhibitory ef-
fects. Interestingly, the linoleic acid–derived 13(S)-HODE,
which has been shown to be the active 15-LOX-1 metabolite
in colon and prostate cancer cells [28,33,41], had no growth
modulatory effects in pancreatic cells when applied in con-
centrations below 50 mM (data not shown). Because none
of the investigated pancreatic cancer cell lines express 15-
LOX-1 at either the mRNA and the protein level, we stably
transfected two pancreatic cancer cell lines (MiaPaCa2 and
S2-O13) with 15-LOX-1 to restore expression of this en-
zyme. Significant growth inhibition and induction of apoptosis
occurred after restoration of 15-LOX-1 activity. These results
are in line with findings in colonic, gastric, and esophageal
cancers where either 15-LOX-1 expression is downregulated
in cancer cells and 13(S)-HODE or upregulation of 15-LOX-1
causes growth inhibition by inducing apoptosis [17,27–
Figure 5. 15-LOX-1 inhibits cell proliferation in transfected MiaPaCa2 and S2-O13 cells shown by (A) cell counting and (B) WST-1 assay. **P V .001; ***P V .0001.
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29,31]. Obviously, overexpression of the transcription fac-
tor GATA-6 in human colon cancer cells contributes to the
multifactorial process of silencing 15-LOX-1 [42]. COX-2
inhibitors induce 15-LOX-1 expression through downregu-
lation of GATA-6 [43]. An important role for the cyclic
guanosine monophosphate/protein kinase G pathway in
the restoration of 15-LOX-1 activity has been suggested
[44]. In addition, IL-4 and IL-13 play important roles in trans-
activating 15-LOX-1, which can then induce p53 expres-
sion and phosphorylation/activation [32,45]. Other research
groups found the 15-LOX-1 promoter to be exclusively
methylated in cells incapable of expressing this enzyme,
whereas 5-Azadc, a potent MTI, induces the expression of
15-LOX-1 in human colorectal cancer cells [35]. Reversing
epigenetic silencing, using a MTI such as 5-Azadc, has
become a new and important target approach for cancer
prevention and therapy [35]. Another possible way to induce
15-LOX-1 expression is to use suberoylanilide hydroxamic
acid, a histone deacetylase inhibitor, which also causes
apoptosis in colorectal cancer cells [46].
It was recently shown that downregulation of 15-LOX-1 is
an early event in the adenoma to carcinoma sequence in
colonic cancer development [30,47]. We observed similar
findings in pancreatic carcinogenesis, because 15-LOX-1 ex-
pression is lost in advanced PanINs as well as cancer cells,
but not in PanIN-1 lesions. These findings are based on im-
munohistochemistry and need to be confirmed, e.g. by laser
capture microdissection in future studies. It is widely accepted
that PanIN-2 and -3 are precursor lesions for ductal adeno-
carcinoma, whereas PanIN-1 lesions are also found in many
nonmalignant pancreatic tissues. Therefore, the switch to de-
velop pancreatic adenocarcinoma may happen at PanIN-2
stage, when 15-LOX-1 is already downregulated.
These findings provide evidence that loss of 15-LOX-1
may play an important role early in pancreatic carcinogene-
sis, possibly as a tumor suppressor gene. Thus, 15-LOX-1
may be an attractive target for the prevention and treatment
of pancreatic cancer.
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